Genome Editing of Induced Pluripotent Stem Cells to Decipher Cardiac Channelopathy Variant

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

卷:72

Article

Garg, Priyanka^1,2  Oikonomopoulos, Angelos^1,2  Chen, Haodong^1,2  Li, Yingxin^1,2  Lam, Chi Keung^1,2  Sallam, Karim^1,2  Perez, Marco^1,2,3  Lux, Robert L.⁴  Sanguinetti, Michael C.^4,5  Wu, Joseph C.^1,2 

[1] Stanford Univ, Stanford Cardiovasc Inst, Stanford, CA 94305 USA

[2] Stanford Univ, Dept Med, Div Cardiol, Stanford, CA 94305 USA

[3] Stanford Univ, Ctr Inherited Cardiovasc Dis, Div Cardiovasc Med, Stanford, CA 94305 USA

[4] Univ Utah, Nora Eccles Harrison Cardiovasc Res & Training In, Salt Lake City, UT USA

[5] Univ Utah, Dept Internal Med, Div Cardiovasc Med, Salt Lake City, UT 84112 USA

关键词: arrhythmia;    genome editing;    induced pluripotent stem cells;    long QT syndrome;    variant of uncertain significance;   

DOI  :  10.1016/j.jacc.2018.04.041

来源: Elsevier

【 摘 要 】

BACKGROUND The long QT syndrome (LQTS) is an arrhythmogenic disorder of QT interval prolongation that predisposes patients to life-threatening ventricular arrhythmias such as Torsades de pointes and sudden cardiac death. Clinical genetic testing has emerged as the standard of care to identify genetic variants in patients suspected of having LQTS. However, these results are often confounded by the discovery of variants of uncertain significance (VUS), for which there is insufficient evidence of pathogenicity. OBJECTIVES The purpose of this study was to demonstrate that genome editing of patient-specific induced pluripotent stem cells (iPSCs) can be a valuable approach to delineate the pathogenicity of VUS in cardiac channelopathy. METHODS Peripheral blood mononuclear cells were isolated from a carrier with a novel missense variant (T983I) in the KCNH2 (LQT2) gene and an unrelated healthy control subject. iPSCs were generated using an integration-free Sendai virus and differentiated to iPSC-derived cardiomyocytes (CMs). RESULTS Whole-cell patch clamp recordings revealed significant prolongation of the action potential duration (APD) and reduced rapidly activating delayed rectifier K+ current (I-Kr) density in VUS iPSC-CMs compared with healthy control iPSC-CMs. ICA-105574, a potent I-Kr activator, enhanced I-Kr magnitude and restored normal action potential duration in VUS iPSC-CMs. Notably, VUS iPSC-CMs exhibited greater propensity to proarrhythmia than healthy control cells in response to high-risk torsadogenic drugs (dofetilide, ibutilide, and azimilide), suggesting a compromised repolarization reserve. Finally, the selective correction of the causal variant in iPSC-CMs using CRISPR/Cas9 gene editing (isogenic control) normalized the aberrant cellular phenotype, whereas the introduction of the homozygous variant in healthy control cells recapitulated hallmark features of the LQTS disorder. CONCLUSIONS The results suggest that the KCNH2(T983I) VUS may be classified as potentially pathogenic. (C) 2018 by the American College of Cardiology Foundation.

【 授权许可】

Free